Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates

Otto Diggelen, Linda Oemardien, N.A.M.E. van der Beek, Marian Haan, Henk Wind, YV Voznyi, D Burke, M Jackson, BG Winchester, Arnold Reuser

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Scopus)

Abstract

Enzyme analysis for Pompe disease in leukocytes has been greatly improved by the introduction of acarbose, a powerful inhibitor of interfering alpha-glucosidases, which are present in granulocytes but not in lymphocytes. Here we show that the application of acarbose in the enzymatic assay employing the artificial substrate 4-methylumbelliferyl-alpha-D-glucoside (MU-alpha Glc) is insufficient to clearly distinguish patients from healthy individuals in all cases. Also, the ratios of the activities without/with acarbose only marginally discriminated Pompe patients and healthy individuals. By contrast, when the natural substrate glycogen is used, the activity in leukocytes from patients (n = 82) with Pompe disease is at most 17% of the lowest control value. The use of artificial substrate in an assay with isolated lymphocytes instead of total leukocytes is a poor alternative as blood samples older than one day invariably yield lymphocyte preparations that are contaminated with granulocytes. To diagnose Pompe disease in leukocytes we recommend the use of glycogen as substrate in the presence of acarbose. This assay unequivocally excludes Pompe disease. To also exclude pseudo-deficiency of acid alpha-glucosidase caused by the sequence change c.271G > A (p.D91N or GAA2; homozygosity in approximately 1:1000 caucasians), a second assay employing MU-alpha Glc substrate plus acarbose or DNA analysis is required.
Original languageUndefined/Unknown
Pages (from-to)416-423
Number of pages8
JournalJournal of Inherited Metabolic Disease
Volume32
Issue number3
DOIs
Publication statusPublished - 2009

Cite this